Bioequivalence of oral administration versus oral spray of a cannabinoid combination (CBD-THC-piperine-PNL capsule)
Pain
Enrolment: 12 · Results not recorded
Loading the evidence…
Nutraceutical · Identity resolved: CHEMBL43185, max_phase 2, no first approval, natural product, not withdrawn. get_mechanism(CHEMBL43185) returned 0 records, so moa_list is empty as a NEGATIVE RESULT, not by omission: ChEMBL holds no curated mechanism of action for piperine. IMPORTANT: every recorded trial uses piperine as a bioavailability enhancer in combination (with curcumin or cannabinoids), NOT as a single agent, and none is a trauma indication. Five further keyword hits (resveratrol, Gly-low, CBD, Ayurvedic multi-ingredient) were REJECTED as non-matches.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Pain
Enrolment: 12 · Results not recorded
ST Elevation Myocardial Infarction (STEMI)
Enrolment: 50 · Results not recorded
Healthy
Enrolment: 6 · Results not recorded
Chronic Kidney Diseases
Enrolment: 30 · Results not recorded
Plasma Levels of Different Curcuminoids Preparations
Enrolment: 24 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Lipopolysaccharide-induced acute lung injury
Piperine attenuated LPS-induced myeloperoxidase activity, lung oedema and TNF-alpha, IL-6 and IL-1beta production, improved lung histology and significantly inhibited LPS-induced NF-kappaB activation.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.